|
2026 Journal Article Cytogenetic testing in newly diagnosed multiple myeloma: real world evidence on clinical features and adverse outcomes for high risk groupsZammar, Ghassan, Augustson, Bradley, Moore, Elizabeth, Wellard, Cameron, Ashrafi, Elham, Sidiqi, Hasib, Lim, Kenneth J. C., Radeski, Dejan, Jackson, Alannah, Bergin, Krystal, Harrison, Simon, Ho, P Joy, King, Tracy, Quach, Hang, Mollee, Peter, Rajagopal, Rajeev, Rosengarten, Brian, Wood, Erica, McQuilten, Zoe and Spencer, Andrew (2026). Cytogenetic testing in newly diagnosed multiple myeloma: real world evidence on clinical features and adverse outcomes for high risk groups. Clinical Lymphoma Myeloma and Leukemia, 26 (4), e492-e501.e1. doi: 10.1016/j.clml.2025.12.005 |
|
2026 Journal Article Wild-Type Transthyretin-Related Amyloidosis in Kindreds: A Play of Chance or New Epiphenomenon?Kang, Katherine, Mollee, Peter, Booth, David and Korczyk, Dariusz (2026). Wild-Type Transthyretin-Related Amyloidosis in Kindreds: A Play of Chance or New Epiphenomenon?. Heart, Lung and Circulation, 35 (3), e25-e28. doi: 10.1016/j.hlc.2025.06.1038 |
|
2026 Journal Article Treatment of patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplantation: position statement of the Myeloma Foundation of Australia Medical and Scientific Advisory GroupSim, Shirlene, McCaughan, Georgia, Zannettino, Andrew, Ho, P. Joy, Joshua, Douglas, Talaulikar, Dipti, Mollee, Peter, Prince, H. Miles, Spencer, Andrew, Harrison, Simon, Lee, Cindy, Augustson, Bradley, Kalff, Anna, Ling, Silvia, Weber, Nicholas, Yong, Angelina and Quach, Hang (2026). Treatment of patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplantation: position statement of the Myeloma Foundation of Australia Medical and Scientific Advisory Group. Internal Medicine Journal, 56 (3) imj.70329, 457-464. doi: 10.1111/imj.70329 |
|
2026 Journal Article An Australian Amyloidosis Network analysis of Australian patients with immunoglobulin light chain amyloidosis treated with bortezomib-based chemotherapyGibbons, Anthea, Chakravorty, Lipi, Sidiqi, Hasib, Ting, Stephen, Kwok, Fiona, Wisniowski, Brendan, Ranjit Anderson, Nirija, Korczyk, Dariusz, Motorna, Olga and Mollee, Peter (2026). An Australian Amyloidosis Network analysis of Australian patients with immunoglobulin light chain amyloidosis treated with bortezomib-based chemotherapy. Internal Medicine Journal, 56 (4) imj.70335, 582-588. doi: 10.1111/imj.70335 |
|
2026 Journal Article A post-market economic evaluation of bortezomib, lenalidomide and dexamethasone versus pre-funding standard of care for newly diagnosed multiple myeloma using registry dataIrving, Adam, Petrie, Dennis, Harris, Anthony, Fanning, Laura, Wood, Erica M., Moore, Elizabeth, Wellard, Cameron, Waters, Neil, Augustson, Bradley, Cook, Gordon, Gay, Francesca, McCaughan, Georgia, Mollee, Peter, Spencer, Andrew and McQuilten, Zoe K. (2026). A post-market economic evaluation of bortezomib, lenalidomide and dexamethasone versus pre-funding standard of care for newly diagnosed multiple myeloma using registry data. PharmacoEconomics, 44 (1), 83-95. doi: 10.1007/s40273-025-01554-4 |
|
2025 Conference Publication Cytogenetic testing in newly diagnosed multiple myeloma (NDMM): Real world evidence of adverse outcomes for high risk groupsZammar, Ghassan, Augustson, Bradley, Moore, Elizabeth, Sidiqi, M Hasib, Wellard, Cameron, Ashrafi, Elham, Harrison, Simon, Radeski, Dejan, Jackson, Alannah, Bergin, Krystal, Ho, Phoebe Joy, King, Tracy, Mollee, Peter, Quach, Hang, Rajagopal, Rajeev, McQuilten, Zoe, Wood, Erica, Rosengarten, Brian and Spencer, Andrew (2025). Cytogenetic testing in newly diagnosed multiple myeloma (NDMM): Real world evidence of adverse outcomes for high risk groups. 67th ASH Annual Meeting, Orlando, FL United States, 6-9 December 2025. Washington, DC United States: American Society of Hematology. doi: 10.1182/blood-2025-2221 |
|
2025 Conference Publication Updated results from the frailty-stratified, randomised controlled bayesian adaptive trial of bortezomib versus lenalidomide in transplant ineligible myeloma (TI NDMM) – the FRAIL-m study (AMaRC 19-01; ALLG MM22)Lim, Sueh-Li, Reynolds, John, Pemberton, Lucy, Wright, Tricia, Lee, Sophie, Mollee, Peter, Shetty, Anita C., Kim, Yu Jin, Helen, Weston, Nina, Byard, Le, Khoa, McQuilten, Zoe, Quach, Hang and Spencer, Andrew (2025). Updated results from the frailty-stratified, randomised controlled bayesian adaptive trial of bortezomib versus lenalidomide in transplant ineligible myeloma (TI NDMM) – the FRAIL-m study (AMaRC 19-01; ALLG MM22). 67th ASH Annual Meeting, Orlando, FL United States, 6-9 December 2025. Washington, DC United States: American Society of Hematology. doi: 10.1182/blood-2025-5842 |
|
2025 Conference Publication Phase 1/2 dose escalation and expansion study of etentamig in patients with relapsed or refractory light chain amyloidosisChakraborty, Rajshekhar, Kastritis, Efstathios, Huart, Antoine, Jaccard, Arnaud, Landau, Heather, Iida, Shinsuke, Motorna, Olga, Mollee, Peter, Ishida, Tadao, Kawano, Yawara, Bhutani, Manisha, D'Souza, Anita, Cowan, Andrew, Hoffman, James, Talati, Chetasi, Rosenberg, Tanya, La Motte-Mohs, Ross, Wang, Fan, Hoffman, David, Fei, Mingwei, Arriola, Emma, Yu, Jovian, Kumar, Shaji, Dispenzieri, Angela, Palladini, Giovanni and Sanchorawala, Vaishali (2025). Phase 1/2 dose escalation and expansion study of etentamig in patients with relapsed or refractory light chain amyloidosis. 67th ASH Annual Meeting, Orlando, FL United States, 6-9 December 2025. Washington, DC United States: American Society of Hematology. doi: 10.1182/blood-2025-692 |
|
2025 Conference Publication Primary analysis of the phase 3 randomized trial of selinexor and lenalidomide versus lenalidomide alone as maintenance therapy post autologous stem cell transplant for patients with newly diagnosed multiple myeloma (ALLG MM23; SEALAND)Rees, Matthew, Lasica, Masa, Kalff, Anna, Low, Michael, Harrup, Rosemary, Lai, Hock Choong, Sidiqi, M Hasib, Wong Doo, Nicole, Routledge, David, Hocking, Jay, Campbell, Philip, Heenan, Jessica, Horvath, Noemi, Chien, Nicole, Renwick, William, McCaughan, Georgia, Eek, Richard, Lenton, Douglas, Gazdar, Sher Gul, Mazumdar, Deepmala, Butcher, Belinda, Mollee, Peter and Quach, Hang (2025). Primary analysis of the phase 3 randomized trial of selinexor and lenalidomide versus lenalidomide alone as maintenance therapy post autologous stem cell transplant for patients with newly diagnosed multiple myeloma (ALLG MM23; SEALAND). 67th ASH Annual Meeting, Orlando, FL United States, 6-9 December 2025. Washington, DC United States: American Society of Hematology. doi: 10.1182/blood-2025-4039 |
|
2025 Journal Article A collaborative approach to amyloidosis and a multidisciplinary care framework – position statement from the International Society of AmyloidosisSanchorawala, Vaishali, Wechalekar, Ashutosh, Mollee, Peter, Sekijima, Yoshiki, Maurer, Mathew S., Leung, Nelson, Schönland, Stefan O. and Kumar, Shaji (2025). A collaborative approach to amyloidosis and a multidisciplinary care framework – position statement from the International Society of Amyloidosis. Amyloid, 32 (4), 1-6. doi: 10.1080/13506129.2025.2570096 |
|
2025 Journal Article Visualizing amyloidosis: the role of radionuclide imaging in systemic amyloidosisRanjit Anderson, Nirija, Dorbala, Sharmila and Mollee, Peter (2025). Visualizing amyloidosis: the role of radionuclide imaging in systemic amyloidosis. Blood Journal, 146 (10) blood.2024026386, 1157-1162. doi: 10.1182/blood.2024026386 |
|
2025 Conference Publication Early Venetoclax Salvage in Systemic Light Chain Amyloidosis: A Retrospective Case SeriesMcVilly, Nicholas, Mollee, Peter, Anderson, Nirija Ranjit, Rowland, James, Korczyk, Dariusz, Sheikh, Nabeel and Abro, Emad (2025). Early Venetoclax Salvage in Systemic Light Chain Amyloidosis: A Retrospective Case Series. International Myeloma Society 22nd Annual Meeting and Exposition, Toronto, Canada, 17-20 September 2025. New York, NY United States: Elsevier. doi: 10.1016/s2152-2650(25)03824-8 |
|
2025 Conference Publication Outcomes of Patients with Multiple Myeloma Post-BCMA Directed Treatment: An Australian PerspectiveLing, Jessica, Moore, Elizabeth, Wellard, Cameron, Spencer, Andrew, Ho, P. Joy, Mollee, Peter, Harrison, Simon, Augustson, Bradley, Quach, Hang and Sidiqi, M. Hasib (2025). Outcomes of Patients with Multiple Myeloma Post-BCMA Directed Treatment: An Australian Perspective. International Myeloma Society 22nd Annual Meeting and Exposition, Toronto, Canada, 17-20 September 2025. New York, NY United States: Elsevier. doi: 10.1016/s2152-2650(25)03520-7 |
|
2025 Conference Publication Identification of Extracardiac Organ Involvement in Systemic Light Chain Amyloidosis using 18F-Florbetaben Positron Emission TomographyAnderson, Nirija Ranjit, Law, Phillip, Harrop, Danielle, Ng, Arnold, Wang, William, Korczyk, Dariusz and Mollee, Peter (2025). Identification of Extracardiac Organ Involvement in Systemic Light Chain Amyloidosis using 18F-Florbetaben Positron Emission Tomography. International Myeloma Society 22nd Annual Meeting and Exposition, Toronto, Canada, 17-20 September 2025. New York, NY United States: Elsevier. doi: 10.1016/s2152-2650(25)03616-x |
|
2025 Conference Publication A Randomized Controlled Trial of Bone-Targeted Exercise for People with Multiple Myeloma: The MyeEx-Impact StudyNicol, Jennifer, King, Tracy, Chong, Jamie, Cunningham, Brent, Hart, Nicolas, Kay, Shelley, Woodrow, Carmel, Beck, Belinda, McDonald, Michelle, Carter, Daniel, Beer, Hayley, Boytar, Alex, Baguley, Brenton, Farley, Morgan, Rose, Grace, Mollee, Peter and Skinner, Tina (2025). A Randomized Controlled Trial of Bone-Targeted Exercise for People with Multiple Myeloma: The MyeEx-Impact Study. International Myeloma Society 22nd Annual Meeting and Exposition, Toronto, Canada, 17-20 September 2025. New York, NY United States: Elsevier. doi: 10.1016/s2152-2650(25)03992-8 |
|
2025 Journal Article Real-world comparison of treatment outcomes for multiple myeloma in elderly transplant ineligible patients receiving first-line VRd, Rd and VCd: Results from the Australian and New Zealand Myeloma and Related Diseases RegistryZhao, Sarah, Wellard, Cameron, Moore, Elizabeth M, Spencer, Andrew, Quach, Hang, Ho, P. Joy, McDonald, Emma-Jane, Mollee, Peter, Harrison, Simon J, Augustson, Bradley, Wood, Erica M, McQuilten, Zoe K and Rajagopal, Rajeev (2025). Real-world comparison of treatment outcomes for multiple myeloma in elderly transplant ineligible patients receiving first-line VRd, Rd and VCd: Results from the Australian and New Zealand Myeloma and Related Diseases Registry. Clinical Lymphoma Myeloma and Leukemia, 26 (1), 49-56. doi: 10.1016/j.clml.2025.08.004 |
|
2025 Journal Article Sustained improvement in health-related quality of life in transplant-ineligible newly diagnosed multiple myeloma treated with daratumumab, lenalidomide, and dexamethasone: MAIA final analysis of patient-reported outcomesPerrot, Aurore, Facon, Thierry, Plesner, Torben, Usmani, Saad Z., Kumar, Shaji, Bahlis, Nizar J., Hulin, Cyrille, Orlowski, Robert Z., Nahi, Hareth, Mollee, Peter, Ramasamy, Karthik, Roussel, Murielle, Jaccard, Arnaud, Delforge, Michel, Karlin, Lionel, Arnulf, Bertrand, Chari, Ajai, Wang, George, Gupta-Werner, Niodita, Kaila, Shuchita, Pei, Huiling, Matt, Kathryn, Gries, Katharine S., Carson, Robin, Borgsten, Fredrik and Weisel, Katja (2025). Sustained improvement in health-related quality of life in transplant-ineligible newly diagnosed multiple myeloma treated with daratumumab, lenalidomide, and dexamethasone: MAIA final analysis of patient-reported outcomes. European Journal of Haematology, 114 (5), 883-889. doi: 10.1111/ejh.14392 |
|
2025 Journal Article Describing the outcomes of frail patients undergoing treatment with systemic therapies for acute myeloid leukaemia: a systematic reviewSia, Aaron, Chopra, Sakshi, Ling, Victoria Y., Fletcher, James, Hubbard, Ruth Eleanor, Mollee, Peter, Gordon, Emily, Reid, Natasha and Hanjani, Leila Shafiee (2025). Describing the outcomes of frail patients undergoing treatment with systemic therapies for acute myeloid leukaemia: a systematic review. Journal of Geriatric Oncology, 16 (3) 102196, 102196. doi: 10.1016/j.jgo.2025.102196 |
|
2025 Conference Publication SUBCUTANEOUS DARATUMUMAB (DARA) plus BORTEZOMIB, CYCLOPHOSPHAMIDE, AND DEXAMETHASONE (VCD) IN NEWLY DIAGNOSED LIGHT CHAIN (AL) AMYLOIDOSIS: OVERALL SURVIVAL AND FINAL MAJOR ORGAN DETERIORATION PROGRESSION-FREE SURVIVAL (PFS) FROM THE PHASE 3 ANDROMEDA STUDYKastritis, E., Palladini, G., Minnema, M. C., Wechalekar, A. D., Jaccard, A., Lee, H. C., Sanchorawala, V., Mollee, P., Lu, J., Schonland, S., Gatt, M. E., Suzuki, K., Kim, K., Cibeira, M. T., Bhutani, M., Beksac, M., Libby, E., Valent, J., Hungria, V., Rosenzweig, M., Bumma, N., Huart, A., Tran, N., Wang, J., Chen, Y., Vasey, S. Y., Schecter, J. M., Vermeulen, J., Comenzo, R. L. and Merlini, G. (2025). SUBCUTANEOUS DARATUMUMAB (DARA) plus BORTEZOMIB, CYCLOPHOSPHAMIDE, AND DEXAMETHASONE (VCD) IN NEWLY DIAGNOSED LIGHT CHAIN (AL) AMYLOIDOSIS: OVERALL SURVIVAL AND FINAL MAJOR ORGAN DETERIORATION PROGRESSION-FREE SURVIVAL (PFS) FROM THE PHASE 3 ANDROMEDA STUDY. 6th European-Myeloma-Network Meeting, Athens Greece, Apr 10-12, 2025. PAVIA: FERRATA STORTI FOUNDATION. |
|
2025 Journal Article Presence of 1q21 gain and amplification may be associated with poorer outcomes in Daratumumab-treated Multiple Myeloma patientsLim, Kenneth J C, Wellard, Cameron, Moore, Elizabeth, Ninkovic, Slavisa, Chng, Wee Joo, Spencer, Andrew, Mollee, Peter, Hocking, Jay, Ho, P. Joy, Janowski, Wojt, Kim, Kihyun, McCaughan, Georgia, Dun, Karen, McQuilten, Zoe, Chen, Fiona and Quach, Hang (2025). Presence of 1q21 gain and amplification may be associated with poorer outcomes in Daratumumab-treated Multiple Myeloma patients. Clinical Lymphoma Myeloma and Leukemia, 25 (4), 243-248. doi: 10.1016/j.clml.2024.11.002 |
